HPV DNA, p16INK4a and mRNA E6*I detection in anogenital cancers - 03/10/14
on behalf of RIS HPV TT and VVAP studies
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
| páginas | 2 |
| Iconografías | 0 |
| Vídeos | 0 |
| Otros | 0 |
Resumen |
HPV infection is a necessary cause for cervical cancer, and it is also causally linked with a range of different attributable fractions to other anogenital and head and neck cancers. The highest HPV DNA involvement in cancers other than cervix has been described in anal cancer (88.3%), followed by vaginal cancers (74.3%), peneal (33.0%) and vulvar (28.6). In high grade pre-neoplastic lesions from vulvar, vaginal, peneal and anal sites a very high HPV DNA detection rate is observed (over 85%). Agreement with biomarkers measuring the viral transforming activity is not 100%. The contribution of these additional markers is not well established when global estimates of HPV-attributable fractions (AF) in human cancer are provided.
Objectives |
To evaluate the contribution of HPV type specific DNA, p16INK4a and type specific mRNA E6*I in anogenital cancers derived from a large repository of parafin-embedded specimens.
Methods |
HPV DNA (SPF-10/LiPA25), p16INK4a and type specific mRNA E6*I are being evaluated in cancer and precancerous lesions of the vulva, vagina, anus and penis. The HPV contribution is estimated by considering different scenarios of biomarkers positivity and correcting for sensitivity drops.
Preliminary results |
p16INK4a positivity among HPV DNA positive cases was 98% in cervical cancer; 95% in anal cancer; 87% in cancer of the vagina; 83% in cancer of the vulva; and 70% in peneal cancer.
The HPV contribution varies depending on the markers used e.g. in vulva cancer contribution would range from 29.4% if considering a positive staining with p16INK4a, 27% with HPV DNA or 22% both combined. The meaning of discrepant results between biomarkers is still subject of discussion. Comprehensive analyses on HPV DNA, p16INK4a and mRNA E6*I in anogenital locations will be provided.
Discussion |
The best approach to estimate HPV contribution in a given tumor has relied mainly on the viral DNA detection. A better understanding of the additional information obtained by other markers like p16INK4a or mRNA may refine our estimates of HPV contribution in related cancers at the population level.
El texto completo de este artículo está disponible en PDF.Esquema
Vol 2014 - N° 465P2
P. 12-13 - septembre 2014 Regresar al número
Artículo precedente
- Rôle des HPV dans les papillomes schneideriens des fosses nasales et des sinus : à propos d’une série de 35 cas
- Goldman-Lévy G, Lassave J, Crampette L, Boulle N, Costes V
- Méthylation de l’ADN des cellules hôtes parmi des femmes africaines infectées par le VIH avec ou sans lésions du col utérin
- Kelly H, Vasiljevic N, Segondy M, Scibor-Bentkowska D, Sawadogo B, Delany S, Mayaud P, Lorincz A
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?